TrialBMC medicine2022

Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial.

Jiong Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.